Hebei Changshan Biochem Pharma (300255) — Capital Reinvestment Ratio

Latest as of June 2025: 0.27x

Hebei Changshan Biochem Pharma (300255) has a Capital Reinvestment Ratio of 0.27x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥70.22 Million) in capital expenditures (CN¥18.63 Million). See 300255 equity financing ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.27x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥70.22 Million
CNY

Capital Expenditures

CN¥18.63 Million
CNY

Data as of

Jun 2025
Most recent filing

Hebei Changshan Biochem Pharma Capital Reinvestment Ratio (2009–2024)

This chart tracks Hebei Changshan Biochem Pharma's Capital Reinvestment Ratio across 10 annual periods. Check Hebei Changshan Biochem Pharma total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Hebei Changshan Biochem Pharma (2009–2024)

Year-by-year Capital Reinvestment Ratio for Hebei Changshan Biochem Pharma from 2009 to 2024. For live market cap and broader valuation context, see how much is Hebei Changshan Biochem Pharma worth.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 4.26x CN¥56.22 Million CN¥239.59 Million ▼ -39.9%
2023 7.10x CN¥33.73 Million CN¥239.32 Million ▼ -94.9%
2022 137.97x CN¥3.13 Million CN¥431.22 Million ▲ +28.6%
2021 107.29x CN¥2.87 Million CN¥308.08 Million ▲ +13277.0%
2018 0.80x CN¥292.81 Million CN¥234.85 Million ▼ -17.8%
2017 0.98x CN¥162.28 Million CN¥158.30 Million ▲ +73.8%
2016 0.56x CN¥171.96 Million CN¥96.52 Million ▼ -68.6%
2011 1.79x CN¥17.04 Million CN¥30.43 Million ▲ +39.0%
2010 1.28x CN¥29.25 Million CN¥37.56 Million ▲ +29.3%
2009 0.99x CN¥24.21 Million CN¥24.05 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow